South Africa has once again made medical history: BEAT Tuberculosis’s clinical study set a global standard for TB care and was published in the New England Journal of Medicine (NEJM), the world’s ...
Could a common over-the-counter anti-inflammatory drug become a new weapon against drug-resistant tuberculosis? Early findings suggest immune benefits, but larger trials are needed to determine ...
Haryana minister Aarti Singh Rao has urged citizens, corporate organisations and voluntary groups to enrol as 'Nikshay Mitras' and support tuberculosis patients by providing nutritional and ...
Introduction Non-adherence to tuberculosis (TB) treatment poses a significant challenge to effective TB management globally and is a major contributor to the emergence of multidrug-resistant TB.
South Africa’s rollout of the twice-yearly HIV prevention injection lenacapavir could transform the fight against HIV, but ...
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...
If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval ...
Eastern Cape, has transformed global treatment of drug-resistant tuberculosis. Furthermore, the study's findings were ...
A phase III trial showed that a 6-month tuberculosis treatment regimen delivered similar results to the longer standard-of-care regimen in patients with pulmonary rifampicin-resistant disease. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results